Bakkenolide DCAS# 18456-03-6 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 18456-03-6 | SDF | Download SDF |
| PubChem ID | 12299954 | Appearance | Powder |
| Formula | C21H28O6S | M.Wt | 408.5 |
| Type of Compound | Miscellaneous | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | [(2R,3R,3aR,4S,7S,7aR)-3-acetyloxy-7,7a-dimethyl-4'-methylidene-2'-oxospiro[3,3a,4,5,6,7-hexahydro-1H-indene-2,3'-oxolane]-4-yl] (Z)-3-methylsulfanylprop-2-enoate | ||
| SMILES | CC1CCC(C2C1(CC3(C2OC(=O)C)C(=C)COC3=O)C)OC(=O)C=CSC | ||
| Standard InChIKey | LWHLMCCRIWZBQO-PDSBHGERSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Bakkenolide D has anti-allergic effect. 2. Bakkenolide B and bakkenolide D demonstrates inhibitory effect on the trachea contraction induced by histamine in vitro, they have obvious anti-histamine activities. |
| Targets | IL Receptor | Histamine Receptor |
Bakkenolide D Dilution Calculator
Bakkenolide D Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.448 mL | 12.2399 mL | 24.4798 mL | 48.9596 mL | 61.1995 mL |
| 5 mM | 0.4896 mL | 2.448 mL | 4.896 mL | 9.7919 mL | 12.2399 mL |
| 10 mM | 0.2448 mL | 1.224 mL | 2.448 mL | 4.896 mL | 6.12 mL |
| 50 mM | 0.049 mL | 0.2448 mL | 0.4896 mL | 0.9792 mL | 1.224 mL |
| 100 mM | 0.0245 mL | 0.1224 mL | 0.2448 mL | 0.4896 mL | 0.612 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 1-Oxobakkenolide S
Catalog No.:BCN7114
CAS No.:18456-02-5
- Bakkenolide B
Catalog No.:BCN7207
CAS No.:18455-98-6
- Madecassic acid
Catalog No.:BCN1013
CAS No.:18449-41-7
- Gefitinib hydrochloride
Catalog No.:BCC1591
CAS No.:184475-55-6
- Gefitinib
Catalog No.:BCN2173
CAS No.:184475-35-2
- Cucurbitacin E
Catalog No.:BCN2300
CAS No.:18444-66-1
- Vitisin B
Catalog No.:BCN6697
CAS No.:142449-90-9
- Picfeltarraenin IV
Catalog No.:BCN2852
CAS No.:184288-35-5
- Dihydromorin
Catalog No.:BCN1149
CAS No.:18422-83-8
- SR 142948
Catalog No.:BCC7323
CAS No.:184162-64-9
- GB 2a
Catalog No.:BCN7425
CAS No.:18412-96-9
- Hautriwaic acid
Catalog No.:BCN4686
CAS No.:18411-75-1
- Taxinine B
Catalog No.:BCN1150
CAS No.:18457-44-8
- 7-Deacetoxytaxinine J
Catalog No.:BCN7677
CAS No.:18457-45-9
- Taxinine J
Catalog No.:BCN6943
CAS No.:18457-46-0
- ROS 234 dioxalate
Catalog No.:BCC7245
CAS No.:184576-87-2
- Mangostanol
Catalog No.:BCN1151
CAS No.:184587-72-2
- Ethyl Coumarin-3-Carboxylate
Catalog No.:BCC9228
CAS No.:1846-76-0
- Nigracin
Catalog No.:BCN1152
CAS No.:18463-25-7
- 2-C-Methyl-D-erythrono-1,4-lactone
Catalog No.:BCN4769
CAS No.:18465-71-9
- Pelargonidin-3-O-glucoside chloride
Catalog No.:BCN3113
CAS No.:18466-51-8
- NAD 299 hydrochloride
Catalog No.:BCC6003
CAS No.:184674-99-5
- Sodium houttuyfonate
Catalog No.:BCN2978
CAS No.:1847-58-1
- Nortropacocaine
Catalog No.:BCN1889
CAS No.:18470-33-2
LC-MS/MS determination of bakkenolide D in rats plasma and its application in pharmacokinetic studies.[Pubmed:23723093]
Biomed Chromatogr. 2013 Sep;27(9):1200-7.
A sensitive and rapid liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for determination of Bakkenolide D (BD), which was further applied to assess the pharmacokinetics of BD. In the LC-MS/MS method, the multiple reaction monitoring mode was used and columbianadin was chosen as internal standard. The method was validated over the range of 1-800 ng/mL with a determination coefficient >0.999. The lower limit of quantification was 1 ng/mL in plasma. The intra- and inter-day accuracies for BD were 91-113 and 100-104%, respectively, and the inter-day precision was <15%. After a single oral dose of 10 mg/kg of BD, the mean peak plasma concentration of BD was 10.1 +/- 9.8 ng/mL at 2 h. The area under the plasma concentration-time curve (AUC0-24 h ) was 72.1 +/- 8.59 h ng/mL, and the elimination half-life (T1/2 ) was 11.8 +/- 1.9 h. In case of intravenous administration of BD at a dosage of 1 mg/kg, the AUC0-24 h was 281 +/- 98.4 hng/mL, and the T1/2 was 8.79 +/- 0.63 h. Based on these results, the oral bioavailability of BD in rats at 10 mg/kg is 2.57%.
Anti-allergic effects of total bakkenolides from Petasites tricholobus in ovalbumin-sensitized rats.[Pubmed:20625987]
Phytother Res. 2011 Jan;25(1):116-21.
The anti-allergic effect of total bakkenolides from the rhizome of Petasites tricholobus (BAPT) was evaluated in an ovalbumin-induced allergic rhinitis model in male Wistar rats. The major components of the bakkenolide fraction are bakkenolide-D, bakkenolide-B, bakkenolide-IIIa and bakkenolide-IVa, which account for 60.04% of the total. The rats were treated with 40 mg/kg, 20 mg/kg, 10 mg/kg or 5 mg/kg BAPT, and 0.942 mg/kg loratadine and 0.5% gum tragacanth were used as positive and negative controls, respectively. The frequency of nose rubbing and sneezing was observed, the number of eosinophils infiltrating into the nasal tissue was counted, and serum levels of IL-4 and histamine were determined by ELISA. The results showed that BAPT had a beneficial effect on allergic rhinitis in ovalbumin-sensitized Wistar rats, which was evidenced by a significant decrease in the frequency of sneezing, the number of eosinophils infiltrating into the nasal tissue, and the serum levels of IL-4 and histamine. BAPT may therefore be a potential antiallergic drug.
